Prices of antihypertensive medicines in sub-Saharan Africa and alignment to WHO's model list of essential medicines

Tropical Medicine and International Health

Volumn 15, Issue 3, 2010, Pages 350-361

  Twagirumukiza, Marc ^a,b   Annemans, Lieven ^c   Kips, Jan G ^b   Bienvenu, Emile ^a   Van Bortel, Luc M ^b  

^a UNIVERSITY OF RWANDA   (Rwanda)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Antihypertensive agents; Drugs, essential medicines; Hypertension; Sub Saharan Africa, drug costs; World Health Organization

Indexed keywords

ACEBUTOLOL; ACETAZOLAMIDE; ALDACTAZINE; AMIODARONE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CAPTOPRIL; CARVEDILOL; CLONIDINE; DILTIAZEM; ENALAPRIL; ESSENTIAL DRUG; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LOSARTAN; METHYLDOPA; NICARDIPINE; NIFEDIPINE; PROPRANOLOL; RAMIPRIL; RESERPINE; SPIRONOLACTONE; VALSARTAN; VERAPAMIL;

DISEASE TREATMENT; DRUG; GROSS DOMESTIC PRODUCT; HEALTH SERVICES; HYPERTENSION; MEDICINE; PRICE DETERMINATION; REGULATORY FRAMEWORK; WORLD HEALTH ORGANIZATION;

AFRICA; ARTICLE; CALCULATION; DATA ANALYSIS; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH SURVEY; HUMAN; HYPERTENSION; INFORMATION PROCESSING; PHARMACY; PRESCRIPTION; UNITED NATIONS; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; ANTIHYPERTENSIVE AGENTS; DRUG COSTS; DRUGS, ESSENTIAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPERTENSION; WORLD HEALTH ORGANIZATION;

SUB-SAHARAN AFRICA;

EID: 77249090278     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02453.x     Document Type: Article

References (61)

1. Aaserud M, Dahlgren AT, Kosters JP et al. (2006) Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 19, CD005979.
2. Anis AH, Guh DP Woolcott J (2003) Lowering generic drug prices: less regulation equals more competition. Medical Care 41, 135 141.
3. Annemans L, Crott R, De Clercq H et al. (1997) Pricing and reimbursement of pharmaceuticals in Belgium. Pharmacoeconomics 11, 203 209.
4. Balasubramaniam K (1996) Health and Pharmaceuticals in Developing Countries: Towards Social Justice and Equity. Consumers International-Regional Office for Asia and the Pacific, Penang, Malaysia.
5. Bloor K, Maynard A Freemantle N (1996) Lessons from international experience in controlling pharmaceutical expenditure. III: regulating industry. BMJ 313, 33 35.
6. Cameron A, Ewen M, Auton M Laing R (2009a) Better measures of affordability required - Authors' reply. Lancet 373, 1081 1082.
7. Cameron A, Ewen M, Ross-Degnan D, Ball D Laing R (2009b) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373, 240 249.
8. Cooper RS, Rotimi CN, Kaufman JS, Muna WF Mensah GA (1998) Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. BMJ 316, 614 617.
9. Courtois X Dumoulin J (1995) Sale of drugs and health care utilization in a health care district in Zaire. Health Policy and Planning 10, 181 186.
10. Dias da Costa JS, Fuchs SC, Olinto MT et al. (2002) Cost-effectiveness of hypertension treatment: a population-based study. São Paulo Medical Journal 120, 100 104.
11. Elliott WJ (1996) The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgraduate Medicine 99, 241 242.
12. Ewen M Dey D (2007) Medicines: Too Costly and Too Scarce. Briefing paper for World Health Assembly delegates 2007. http://www.haiweb.org/medicineprices/ 2005/PricingbriefingpaperFINAL.doc. Accessed 17 June 2009.
13. Fischer MA Avorn J (2004) Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 291, 1850 1856.
14. Gaziano TA (2005) Cardiovascular disease in the developing world and its cost-effective management. Circulation 112, 3547 3553.
15. Gelders S, Ewen M, Noguchi N Laing R (2006) Price, Availability and Affordability: an International Comparison of Chronic Disease Medicines. http://mednet3.who.int/medprices/CHRONIC.pdf. Accessed 20 February 2008.
16. Guimier JM, Candau D, Garenne M Teulieres L (2005) Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal. Sante 15, 41 52.
17. HAI (2008) Monitoring Medicine Prices, Availability and Affordability : Pilot Countries' Reports. http://www.haiweb.org/medicineprices/. Accessed 5 September 2008.
18. Helgeland A, Strommen R, Hagelund CH Tretli S (1986) Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1, 872 875.
19. Hughes D Fiander A (1989) The Bamako initiative. BMJ 299, 683.
20. Jayasinghe S, Jayasinghe S De Silva P (2003) State can make drugs available cheaply to poor people. BMJ 326, 553.
21. Kaplan NM (1990) The cost-effectiveness of antihypertensive drugs. JAMA 263, 2888 2889.
22. Kindermans JM Matthys F (2001) Introductory note: the access to Essential Medicines Campaign. Tropical Medicine and International Health 6, 955 956.
23. Laing R (1991) Essential drugs programmes in Africa. Africa Health 14, 32 33.
24. Levison L Laing R (2003) The hidden costs of essential medicines. Essential Drugs Monitor 33, 20 21.
25. Lindholm LH Werko L (1996) Comparing hypertension guidelines. Cost effectiveness analyses have been carried out in Sweden. BMJ 313, 1203 1204.
26. Linjer E, Hedner T, Jonsson B et al. (2005) Cost analysis of different pharmacological treatment strategies in elderly hypertensives. Blood Pressure 14, 107 113.
27. Mallet HP, Njikam A Scouflaire SM (2001) Evaluation of prescription practices and of the rational use of medicines in Niger. Sante 11, 185 193.
28. Mancia G, De Backer G, Dominiczak A et al. (2007) 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 25, 1105 1187.
29. Mayor S (2003) Thiazides could achieve major cost savings in uncomplicated hypertension. BMJ 327, 521.
30. Mendis S, Fukino K, Cameron A et al. (2007) The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bulletin of the World Health Organization 85, 279 288.
31. Montgomery RW (1998) Hypertension treatment and control in Sub-saharan Africa. Amount spent on health care per capita is same as cost of a McDonald's. BMJ 317, 76.
32. MSH WHO (2007) International Drug Price Indicator Guide 2007. 2007 edn. MSH &WHO, Geneva.
33. Mugisha F, Kouyate B, Gbangou A Sauerborn R (2002) Examining out-of-pocket expenditure on health care in Nouna, Burkina Faso: implications for health policy. Tropical Medicine and International Health 7, 187 196.
34. Niens LM Brouwer WB (2009) Better measures of affordability required. Lancet 373, 1081 1082.
35. Odell TW Gregory MC (1995) Cost of hypertension treatment. Journal of General Internal Medicine 10, 686 688.
36. Pardell H, Tresserras R, Armario P Hernandez Del Rey R (2000) Pharmacoeconomic considerations in the management of hypertension. Drugs 59 (Suppl. 2 13 20.
37. Perez-Casas C, Herranz E Ford N (2001) Pricing of drugs and donations: options for sustainable equity pricing. Tropical Medicine and International Health 6, 960 964.
38. Philipp T, Anlauf M, Distler A et al. (1997) Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 315, 154 159.
39. Quick JD, Hogerzeil HV, Velasquez G Rago L (2002) Twenty-five years of essential medicines. Bulletin of the World Health Organization 80, 913 914.
40. Quick JD, Boohene NA, Rankin J Mbwasi RJ (2005) Medicines supply in Africa. BMJ 331, 709 710.
41. Reidenberg MM (2007) World Health Organization program for the selection and use of essential medicines. Clinical Pharmacology and Therapeutics 81, 603 606.
42. Richard V (2004) Funding for healthcare in sub-Saharan Africa: cost recovery. Médecine Tropicale 64, 337 340.
43. Richards T (1986) Drugs in developing countries: inching towards rational policies. British Medical Journal 292, 1347 1348.
44. Seedat YK (2007) Impact of poverty on hypertension and cardiovascular disease in sub-Saharan Africa. Cardiovascular Journal of Africa 18, 316 320.
45. Shulman NB, Martinez B, Brogan D, Carr AA Miles CG (1986) Financial cost as an obstacle to hypertension therapy. American Journal of Public Health 76, 1105 1108.
46. Smith MK Tickell S (2003) The essential drugs concept is needed now more than ever. Transactions of the Royal Society of Tropical Medicine and Hygiene 97, 2 5.
47. Spurgeon D (2004) NIH promotes use of lower cost drugs for hypertension. BMJ 328, 539.
48. Turshen M (2001) Reprivatizing pharmaceutical supplies in Africa. Journal of Public Health Policy 22, 198 225.
49. United Nations (2008) Millennium Development Goal (MDG) Gap Task Force 8: Delivering on the Global Partnership for Achieving the MDGs, Report 2008. http://www.un.org/esa/policy/mdggap. Accessed 5 April 2009.
50. Walker AR Wadee AA (2000) In the rationing of healthcare in indigent African populations, which services should come first? Journal of the Royal Society of Health 120, 152 157.
51. Waller PC Ramsay LE (1989) Predicting acute gout in diuretic-treated hypertensive patients. Journal of Human Hypertension 3, 457 461.
52. WHO (1999) Operational Principles for Good Pharmaceutical Procurement. WHO, Geneva.
53. WHO (2003) The selection and use of essential medicines 2002. 12th Model list of essential medicines. World Health Organization Technical Report Series 914, 58 59.
54. WHO (2004a) The World Medicines Situation. WHO, Geneva.
55. WHO (2004b) The selection and use of essential medicines 2003. 13th Model list of essential medicines. World Health Organization Technical Report Series 920, 80 82.
56. WHO (2006) The selection and use of essential medicines 2005. 14th model list of essential medicines. World Health Organization Technical Report Series 933, 76 78.
57. WHO (2007) The selection and use of essential medicines 2007. 15th Model list of essential medicines. World Health Organization Technical Report Series 946, 104 105.
58. WHO (2008) ATC/DDD Index 2008. http://www.whocc.no/atcddd/. Accessed 25 May 2008.
59. WHO HAI (2008) Medicine Prices: a New Approach to Measurement. http://www.haiweb.org/medicineprices/manual/manuals/MedicinePrices.pdf. Accessed 5 December 2008.
60. WHO HAI (2009) Measuring Medicine Prices, Availability, Affordability and Price Components. WHO, Geneva.
61. World Bank (2007) World Development Indicators (WDI) Database, 2007. http://www.congre.co.jp/neurosci2009/english/registration/images/gni-per-capita. pdf. Accessed 5 September 2009.